# What the COURAGE MRI substudy measured in the thigh

- Article ID: research-394
- Product: Trevogrumab (trevogrumab-1mg-3ml)
- Canonical page: https://heritagebiolabs.com/research-library/articles/394-what-the-courage-mri-substudy-measured-in-the-thigh
- Product collection: https://heritagebiolabs.com/research-library/products/trevogrumab
- Product page: https://heritagebiolabs.com/product/trevogrumab-1mg-3ml
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2024, 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains linked by peptide bonds. Some bind particular proteins, and larger proteins can recognize targets through a similar principle. Trevogrumab is an investigational monoclonal antibody, a large protein engineered to block myostatin, also called GDF8. In 2026, the COURAGE trial sponsor reported an MRI substudy that asked whether adding this antibody to semaglutide changed thigh muscle volume. [1, 2, 3]

The trial’s body composition measurements included two types of scans. Dual-energy X-ray absorptiometry, or DXA, can estimate lean mass across the body. MRI can provide a more direct view of the size of particular tissues in a chosen region. In this substudy, investigators examined fat-free muscle volume in the thigh. That let them ask a question about a specific group of muscles alongside the whole-body lean mass comparison. [1]

The sponsor reported that the groups assigned to the antibody with semaglutide lost less thigh muscle volume than the group receiving semaglutide alone among participants with evaluable MRI data. The sponsor described the differences as representing roughly 70% preservation of the amount otherwise lost in the comparison group. This is a relative comparison of losses. It does not indicate that the groups gained 70% in muscle volume or that all participants had the same response. [1]

The finding was presented in a sponsor report about a predefined substudy. An MRI volume measurement does not measure how much force a person can generate or how easily they can walk or climb stairs. The result is specific to the trial’s studied arms and participants with scans that could be analyzed. Trevogrumab remains investigational. [1, 2]

## Sources

1. Regeneron Pharmaceuticals, Inc. Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss. Sponsor results announcement (publication 2026-10-01). <https://newsroom.regeneron.com/news-releases/news-release-details/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass>
2. Regeneron Pharmaceuticals, Inc. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity. ClinicalTrials.gov (publication 2024-03-07, record updated 2026-09-01). <https://clinicaltrials.gov/study/NCT06299098>
3. Jason W. Mastaitis et al. GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nature Communications (publication 2025-05-13). <https://pmc.ncbi.nlm.nih.gov/articles/PMC12075787/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 079 - TIRZ IGF-1 LR3 and Trevogrumab.docx; article 394; content SHA-256 d6b7641799fe7c8e7841f14fa76ffffcdfd88c346350a71b8fdf3eb8ba5c6a7e.
